Movement Alert｜ZAI LAB Rises 5.86% in Regular Trading, Major Institutional Stake Increase Boosts Market Confidence

Market Focus09-02

On September 2, ZAI LAB rose 5.86% in regular trading, trading at 20.42 HKD/share, with turnover of approximately 33.04 million HKD. The stock rebounded notably after earlier pressure following its interim results release.

On the news front, prominent healthcare-focused fund RTW Investments purchased approximately 12.31 million shares on August 20 at an average price of 26 USD per share, totaling roughly 320 million USD. The transaction lifted RTW's stake from 7.17% to 8.25%, signaling strong institutional conviction in the company's long-term value.

Additionally, partner argenx announced positive top-line results from its ALKIVIA Phase 3 trial of FcRn antagonist efgartigimod for adult autoimmune myositis. ZAI LAB holds exclusive development and commercialization rights for efgartigimod in Greater China, positioning the company to further expand its autoimmune disease franchise if the indication gains regulatory approval.

However, the company's H1 financials showed net product revenue declining 6% year-over-year to 201.3 million USD, while net loss widened 14% to 102 million USD, primarily due to increased licensing fees and competitive pressures on key products.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1154838075?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-02 09:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1154838075","market":"hk","top_or_hot":-1,"title":"Movement Alert｜ZAI LAB Rises 5.86% in Regular Trading, Major Institutional Stake Increase Boosts Market Confidence","media":"Market Focus","content":"<p><p>On September 2, ZAI LAB rose 5.86% in regular trading, trading at 20.42 HKD/share, with turnover of approximately 33.04 million HKD. The stock rebounded notably after earlier pressure following its interim results release.</p><p>On the news front, prominent healthcare-focused fund RTW Investments purchased approximately 12.31 million shares on August 20 at an average price of 26 USD per share, totaling roughly 320 million USD. The transaction lifted RTW's stake from 7.17% to 8.25%, signaling strong institutional conviction in the company's long-term value.</p><p>Additionally, partner argenx announced positive top-line results from its ALKIVIA Phase 3 trial of FcRn antagonist efgartigimod for adult autoimmune myositis. ZAI LAB holds exclusive development and commercialization rights for efgartigimod in Greater China, positioning the company to further expand its autoimmune disease franchise if the indication gains regulatory approval.</p><p>However, the company's H1 financials showed net product revenue declining 6% year-over-year to 201.3 million USD, while net loss widened 14% to 102 million USD, primarily due to increased licensing fees and competitive pressures on key products.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜ZAI LAB Rises 5.86% in Regular Trading, Major Institutional Stake Increase Boosts Market Confidence</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜ZAI LAB Rises 5.86% in Regular Trading, Major Institutional Stake Increase Boosts Market Confidence\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-02 09:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 2, ZAI LAB rose 5.86% in regular trading, trading at 20.42 HKD/share, with turnover of approximately 33.04 million HKD. The stock rebounded notably after earlier pressure following its interim results release.</p><p>On the news front, prominent healthcare-focused fund RTW Investments purchased approximately 12.31 million shares on August 20 at an average price of 26 USD per share, totaling roughly 320 million USD. The transaction lifted RTW's stake from 7.17% to 8.25%, signaling strong institutional conviction in the company's long-term value.</p><p>Additionally, partner argenx announced positive top-line results from its ALKIVIA Phase 3 trial of FcRn antagonist efgartigimod for adult autoimmune myositis. ZAI LAB holds exclusive development and commercialization rights for efgartigimod in Greater China, positioning the company to further expand its autoimmune disease franchise if the indication gains regulatory approval.</p><p>However, the company's H1 financials showed net product revenue declining 6% year-over-year to 201.3 million USD, while net loss widened 14% to 102 million USD, primarily due to increased licensing fees and competitive pressures on key products.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09688","symbol_name":"再鼎医药","start_time":0,"source_url":"","article_id":"1154838075","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1154838075","pubTimestamp":1788314163,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 2, ZAI LAB rose 5.86% in regular trading, trading at 20.42 HKD/share, with turnover of approximately 33.04 million HKD. The stock rebounded notably after earlier pressure following its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09688":"再鼎医药"},"translate_title":"走势提醒|再鼎医药常规交易上涨5.86%，主要机构增持提振市场信心","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09688":1},"content_text":"On September 2, ZAI LAB rose 5.86% in regular trading, trading at 20.42 HKD/share, with turnover of approximately 33.04 million HKD. The stock rebounded notably after earlier pressure following its interim results release.On the news front, prominent healthcare-focused fund RTW Investments purchased approximately 12.31 million shares on August 20 at an average price of 26 USD per share, totaling roughly 320 million USD. The transaction lifted RTW's stake from 7.17% to 8.25%, signaling strong institutional conviction in the company's long-term value.Additionally, partner argenx announced positive top-line results from its ALKIVIA Phase 3 trial of FcRn antagonist efgartigimod for adult autoimmune myositis. ZAI LAB holds exclusive development and commercialization rights for efgartigimod in Greater China, positioning the company to further expand its autoimmune disease franchise if the indication gains regulatory approval.However, the company's H1 financials showed net product revenue declining 6% year-over-year to 201.3 million USD, while net loss widened 14% to 102 million USD, primarily due to increased licensing fees and competitive pressures on key products.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1154838075","isCrawlerRequest":true}